# ELM-2 (NCT03888105)

> A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03888105
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Regeneron Pharmaceuticals
- Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions: Odronextamab
- Enrollment: 515
- Primary outcome: Objective Response Rate (ORR), as assessed by independent central review
- Primary outcome: ORR, as assessed by independent central review

## Commentary we found

- Podcasts: 16
- YouTube: 12
- X threads: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=elm-2-nct03888105

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03888105", "email": "<work email>"}; the inbox owner confirms by the emailed link.